Fundraising FoxLilly Ventures
Seed–Late Stage · 1 people tracked
Find your way into Lilly Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Aziz Gilani to introduce you to Armen Shanafelt
You →Aziz · together at Kauffman Fellows Class 14 →Armen
Sign up to find every way you can get introduced to Lilly Ventures
- Your email: who you already know at Lilly Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Lilly Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Team · 1 people
from curatedWhat they invest in
from 18 of 18 portfolio companiesBiotech ×15Healthtech ×9AI & Machine Learning ×4Deep Tech ×4Digital Health ×4Longevity ×3Direct to Consumer ×1Enterprise Software ×1
HQs:United States×14Switzerland×1
Investments · 18 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 12023 · 12020 · 12017 · 12016 · 12015 · 22009 · 112 dated
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalOrbiMed+19 more
Daré Bioscience is a female-led biotech company developing treatments for women's health conditions that are overlooked in the healthcare industry.
BiotechDigital HealthDirect to ConsumerFemTechHealthtechSan Diego, US
MarDee Haring-Layton(Chief Accounting Officer)inSabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)
Co-investorsPolaris PartnersVenrock
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJJDCJohnson & Johnson Innovation – JJDCRA CapitalStarfish Ventures
Cerulean builds AI agents that automate high-value business processes and improve productivity for organizations.
AI & Machine LearningEnterprise SoftwareSaaSSector Agnostic
Kieran Luke(Founder)in
Co-investorsMastryMosaic General Partnership, LLCBessemer Venture PartnersLux CapitalVenrock
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Saints CapitalAbingworth
The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause.
BiotechHealthtechImpact & Social GoodLongevityZug, CH
Joshua C. Herring(President & CEO)in
Co-investorsLongeVCFounders FundKhosla VenturesThrive Capital
Longevity Health provides health insurance plans focused on optimizing quality of life for people in long-term care through value-based, personalized solutions addressing physical, mental, emotional, and social well-being.
Digital HealthHealthtechInsurTechLongevity
BoardRené Lerer(President of Guidewell Mutual Holding Company)
Co-investorsK2 HealthVenturesAhren Innovation CapitalFounders FundKhosla VenturesLightspeed Venture PartnersNestle+1 more
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsSanofi VenturesAtlas VentureHatteras Venture PartnersOmega FundsRoche Venture Fund
Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsNew Enterprise Associates (NEA)ForbionNovo Holdings
Persist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.
AI & Machine LearningBiotechHealthtechMedical DevicesRoboticsSacramento, US
Karthik Raman(Founder)inChristopher Shelner(Founder)in
Co-investors2048 VenturesGlobal BrainGood AI CapitalJovonoPioneerSpero Ventures+5 more
Quarry Thera is a biotech developing oral small-molecule medicines based on induced-proximity pharmacology, using molecular glues and heterobifunctional compounds.
BiotechDeep TechNew Haven, US
Craig Crews(Co-Founder & Scientific Advisor)inMikael Dolsten, M.D., Ph.D.(Co-founder and Executive Chairman of the Board)Craig Crews, Ph.D.(Co-Founder & Scientific Advisor)Dan McHugh(Manager)Tim Shannon(CEO and Board Member)inJeanne Magram(Chief Scientific Officer)in
Co-investorsYosemiteF-Prime CapitalCanaan Partners
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsDecheng CapitalLAVLilly Asia VenturesVivo Capital
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in
Co-investorsARCH Venture PartnersOUP (Osage University Partners)Ridgeback CapitalVenrock
Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US
Alice Zhang(Co-founder & CEO)inJason Chen(Cofounder)inEmily Ripka(Head of Product & Engineering)in
Co-investorsAgent CapitalBOLD LongevityDraper AssociatesFitz Gate VenturesGreat Oaks Venture CapitalKarlin Ventures+25 more
Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.
Digital HealthHealthtechTravel & HospitalityWellness & Fitness
Co-investorsAstellas Venture Management LLCHatteras Venture PartnersNovartis Venture FundWoodford Investment Management
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 4
3 IPOs · 1 acquisitions · showing 3BioAge LabsNASDAQ: BIOADare BioscienceNASDAQ: DAREProtagonist TherapeuticsNASDAQ: PTGX
Portfolio news
latest coverage across their companies
Persist AI · prnewswire.com · May 19, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Dare Bioscience | 9.0% | $6.00 | Apr 2015 | $14.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Lilly Ventures made?
- Lilly Ventures has 18 tracked investments, 4 of which have exited, including 4 dated in the last 24 months.
- What stage does Lilly Ventures invest at?
- Lilly Ventures invests at the Seed, Late Stage stages.
Similar investors
83North is a global venture capital firm that invests in and helps entrepreneurs build large, category-defining companies, backing startups across multiple stages and sectors.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.
AirTree Ventures runs Pathfinders, a free four-week in-person program in Sydney for young builders (high-school graduates up to age 23) to work on a real product, access the AirTree team and founders, and build a peer network.